Sugi Predict

Sugi Predict / Compounds / SCHEMBL4517020

SCHEMBL4517020

SCHEMBL4517020

Cc1cc(S(=O)(=O)N[C@@H](C)COc2ccccc2C(N)=O)c(C)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 6/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ PARP1 P09874 2/20 0.41
▸ NPSR1 Q6W5P4 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ NR3C1 P04150 2/20 0.41
▸ IRAK4 Q9NWZ3 1/20 0.40
▸ LMNA P02545 5/20 0.39
▸ HPGD P15428 3/20 0.39
▸ AKR1C1 Q04828 1/20 0.39
▸ MAPT P10636 3/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NR1I2 O75469 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ ADRA2A P08913 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4519006 0.82 HTT (0.43) HTTL3MBTL1PARP1NR3C1IRAK4
SCHEMBL4512042 0.82 NR3C1 (0.60) HTTL3MBTL1PARP1ALDH1A1NR3C1
SCHEMBL4511719 0.81 PARP1 (0.46) HTTL3MBTL1PARP1NR3C1IRAK4
SCHEMBL4512981 0.80 NR3C1 (0.61) HTTL3MBTL1NR3C1
SCHEMBL4517755 0.80 NR3C1 (0.61) HTTL3MBTL1NR3C1
SCHEMBL4512045 0.79 L3MBTL1 (0.55) HTTL3MBTL1PARP1NR3C1IRAK4
SCHEMBL4519749 0.71 NR3C1 (0.47) HTTL3MBTL1PARP1NR3C1IRAK4
SCHEMBL4559868 0.70 GAA (0.43) HTTL3MBTL1PARP1HPGDMAPT
SCHEMBL13763533 0.70 HTT (0.71) HTTPARP1ALDH1A1IRAK4LMNA
SCHEMBL4510480 0.69 ALPL (0.48) HTTL3MBTL1NPSR1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 — — US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 — — US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 — — US disclosed
EP-1807391-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AstraZeneca AB (SE) 2007-07-18 — — EP disclosed
WO-2006046916-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2006-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 HTT 3337/4885L3MBTL1 4844/4885PARP1 4799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.